12:00 AM
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

ADNS-300 System regulatory update

Neurotech said it received CE Mark approval for ADNS-300 System to treat refractory epilepsy. The company...

Read the full 56 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >